The Global Generic Drugs Market Will Reach $356.8bn in 2020

Thursday 2 June 2016, Amsterdam

A new report, now available on ASDReports, predicts that the Global Generics Drugs market will reach $356.8bn in 2020. This forecast and others appear in Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets, published in April 2016.

This report examines the current and future trends in the growing generic drugs market. Population growth and changing demographics with increasing proportions of elderly people in most markets will enhance growth of the market. The rapid emergence of the middle-class in many emerging markets will also contribute to growth. Cost-pressures that encourage healthcare providers and governments to introduce policies to further encourage the use of generic drugs will further bring growth to the generics market over the years.

In this report, we examine in detail the global generic drugs market, and provide analyses and forecasts for regional and national markets. Historical revenues, where available, have also been added to strengthen our analysis and demonstrate how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety, features and more.

This report provides revenue forecasts to 2026 for the Generic Drugs market, including forecasts for leading regional and national markets: US, EU5 (Germany, UK, France, Italy and Spain), Asia-Pacific (China, Japan and India) as well as emerging markets (Brazil, Russia, Mexico, South Korea and Turkey). The report also discusses selected leading companies in the market. These companies include Teva, Mylan, Novartis (Sandoz), Sun Pharma, Pfizer, Abbott, Allergan, Fresenius Kabi, Sanofi and Aspen.